These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

430 related items for PubMed ID: 22609029

  • 1. [Elevated HDL is the main negative risk factor for coronary artery disease in the elderly patient with calcific aortic valve disease].
    Bordalo AD, Nobre AL, Dantas M, Cravino J.
    Rev Port Cardiol; 2012 Jun; 31(6):415-24. PubMed ID: 22609029
    [Abstract] [Full Text] [Related]

  • 2. Risk factors for coronary artery disease in patients with elevated high-density lipoprotein cholesterol.
    DeFaria Yeh D, Freeman MW, Meigs JB, Grant RW.
    Am J Cardiol; 2007 Jan 01; 99(1):1-4. PubMed ID: 17196452
    [Abstract] [Full Text] [Related]

  • 3. The relation between homocysteine and calcific aortic valve stenosis.
    Gunduz H, Arinc H, Tamer A, Akdemir R, Ozhan H, Binak E, Uyan C.
    Cardiology; 2005 Jan 01; 103(4):207-11. PubMed ID: 15838165
    [Abstract] [Full Text] [Related]

  • 4. Determinants of serum HDL-C level in a Tehran urban population: the Tehran Lipid and Glucose Study.
    Azizi F, Raiszadeh F, Salehi P, Rahmani M, Emami H, Ghanbarian A, Hajipour R.
    Nutr Metab Cardiovasc Dis; 2002 Apr 01; 12(2):80-9. PubMed ID: 12189907
    [Abstract] [Full Text] [Related]

  • 5. A tertiary care hospital-based study of conventional risk factors including lipid profile in proven coronary artery disease.
    Goel PK, Bharti BB, Pandey CM, Singh U, Tewari S, Kapoor A, Garg N, Sinha N.
    Indian Heart J; 2003 Apr 01; 55(3):234-40. PubMed ID: 14560932
    [Abstract] [Full Text] [Related]

  • 6. Lipid profile in patients with coronary artery disease.
    Haddad FH, Omari AA, Shamailah QM, Malkawi OM, Shehab AI, Mudabber HK, Shubaki MK.
    Saudi Med J; 2002 Sep 01; 23(9):1054-8. PubMed ID: 12370711
    [Abstract] [Full Text] [Related]

  • 7. Metabolic factors clustering, lipoprotein cholesterol, apolipoprotein B, lipoprotein (a) and apolipoprotein E phenotypes in premature coronary artery disease in French Canadians.
    Weber M, McNicoll S, Marcil M, Connelly P, Lussier-Cacan S, Davignon J, Latour Y, Genest J.
    Can J Cardiol; 1997 Mar 01; 13(3):253-60. PubMed ID: 9117913
    [Abstract] [Full Text] [Related]

  • 8. Comparison of cardiovascular risk and lipid profiles in patients undergoing aortic valve surgery versus those undergoing coronary artery bypass grafting.
    Novaro GM, Pearce GL, Sprecher DL, Griffin BP.
    J Heart Valve Dis; 2001 Jan 01; 10(1):19-24. PubMed ID: 11206763
    [Abstract] [Full Text] [Related]

  • 9. Lipid levels in patients hospitalized with coronary artery disease: an analysis of 136,905 hospitalizations in Get With The Guidelines.
    Sachdeva A, Cannon CP, Deedwania PC, Labresh KA, Smith SC, Dai D, Hernandez A, Fonarow GC.
    Am Heart J; 2009 Jan 01; 157(1):111-117.e2. PubMed ID: 19081406
    [Abstract] [Full Text] [Related]

  • 10. Novel atherogenesis markers for identification of patients with a multivessel coronary artery disease.
    Krecki R, Drozdz J, Szcześniak P, Orszulak-Michalak D, Krzemińska-Pakuła M.
    Kardiol Pol; 2008 Nov 01; 66(11):1173-80; discussion 1181-2. PubMed ID: 19105094
    [Abstract] [Full Text] [Related]

  • 11. Serum lipid and lipoprotein profile abnormality in predicting the risk of coronary artery disease in non-diabetic patients attending NMCTH, Birgunj.
    Adak M, Shivapuri JN.
    Nepal Med Coll J; 2010 Sep 01; 12(3):158-64. PubMed ID: 21446364
    [Abstract] [Full Text] [Related]

  • 12. High-density lipoprotein cholesterol in coronary artery disease patients: is it as low as expected?
    Uzunlulu M, Oğuz A, Tigen K.
    Anadolu Kardiyol Derg; 2005 Dec 01; 5(4):268-70. PubMed ID: 16330390
    [Abstract] [Full Text] [Related]

  • 13. Association between circulating oxidised low-density lipoprotein and fibrocalcific remodelling of the aortic valve in aortic stenosis.
    Côté C, Pibarot P, Després JP, Mohty D, Cartier A, Arsenault BJ, Couture C, Mathieu P.
    Heart; 2008 Sep 01; 94(9):1175-80. PubMed ID: 17932090
    [Abstract] [Full Text] [Related]

  • 14. Independent association between triglycerides and coronary artery disease in Taiwanese type 2 diabetic patients.
    Tseng CH, Tseng CP, Chong CK, Cheng JC, Tai TY.
    Int J Cardiol; 2006 Jul 28; 111(1):80-5. PubMed ID: 16213608
    [Abstract] [Full Text] [Related]

  • 15. HMG-CoA reductase inhibitor (Statin) therapy and coronary atherosclerosis in Japanese subjects: role of high-density lipoprotein cholesterol.
    Tani S, Nagao K, Hirayama A.
    Am J Cardiovasc Drugs; 2011 Dec 01; 11(6):411-7. PubMed ID: 22149320
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J, Ikeda Y, Kuribayashi T, Kajiwara K, Biro S, Yamamoto K, Ageta M, Kobori S, Saikawa T, Otonari T, Kono S.
    Clin Ther; 2008 Jun 01; 30(6):1089-101. PubMed ID: 18640465
    [Abstract] [Full Text] [Related]

  • 20. Long-term (18-month) efficacy of atorvastatin therapy in type 2 diabetics at cardiovascular risk.
    Velussi M.
    Nutr Metab Cardiovasc Dis; 2002 Feb 01; 12(1):29-35. PubMed ID: 12125227
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.